DERMATOLOGICAL INTERVENTIONS IN THE MANAGEMENT OF STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS

Abstract

 Introduction: Stevens-Johnson syndrome and toxic epidermal necrolysis are severe mucocutaneous reactions, usually drug-induced, characterized by epidermal necrosis, skin detachment, mucosal involvement, and a high risk of mortality (CREAMER et al., 2016; SCHWARTZ et al., 2013). Objective: To analyze dermatological and systemic interventions used in the management of Stevens-Johnson syndrome, focusing on skin care, discontinuation of the causative agent, supportive care, and immunomodulation. Methodology: A systematic, descriptive, and qualitative review, according to PRISMA 2020 (PAGE et al., 2021), was conducted using PubMed, BVS, and SciELO databases between 2021 and 2026, using DeCS/BVS descriptors related to Stevens-Johnson syndrome, toxic epidermal necrolysis, dermatology, therapeutics, and immunosuppressants. Results: Six studies were selected. The evidence reinforces the need for early discontinuation of the suspected drug, wound care, support in a specialized unit, and careful evaluation of systemic therapies such as corticosteroids, cyclosporine, etanercept, intravenous immunoglobulin, and therapeutic combinations (KRIDIN et al., 2021; HOUSCHYAR et al., 2021; JACOBSEN et al., 2022; ZHANG et al., 2022; CHANG et al., 2022; HEUER et al., 2025). Conclusion: dermatological management should be early, interdisciplinary, and individualized, prioritizing rapid recognition, skin support, and cautious selection of immunomodulation (CREAMER et al., 2016; JACOBSEN et al., 2022).